SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that clinical data highlighting real-world
performance of the Company's Target Selector™ platform for
detecting actionable biomarkers in lung cancer patients will be
presented at the 2019 IASLC World Conference on Lung Cancer being
held September 7-10, 2019 at the Fira
Gran Via Exhibition and Conference Center in Barcelona, Spain. The poster features clinical
experience data from over 1,400 blood samples drawn from patients
diagnosed with non-small cell lung cancer (NSCLC) and collected and
shipped using Biocept's CEE-Sure™ specimen collection tubes,
specifically designed for liquid biopsy testing. Abstracts for
posters to be presented at this conference can be found at
library.iaslc.org.
Poster presentation details are as follows:
Title: The Dynamic Range of Mutant Allele Fraction
Detected in Patients with NSCLC: Clinical Experience Data and
Clinical Implications
Session Category/Title: P1.14/Targeted Therapy
Session
Session Date and Time: Sunday September 8, 2019,
09:45am-18:00pm (CEST)
Location: Fira Gran Via Conference Center, Exhibit
Hall, Poster Session P1.14
"To date, our clinical experience has demonstrated consistent
performance for detecting actionable mutations in the ctDNA of
patients with NSCLC as low as 0.01% mutant allele frequency," said
Biocept's Senior Vice President and Senior Medical Director
Veena Singh, MD. "The ability to
detect mutations at such low levels can serve to expand the cohort
of patients that could potentially benefit from the use of targeted
therapies and to monitor their progression or therapeutic response,
as these patients might be missed with less sensitive technologies.
We are also pleased to demonstrate the robust performance of our
CEE-Sure™ blood collection tubes which are designed to stabilize
cells in a given blood sample to minimize the presence of non-tumor
DNA in the plasma fraction. We believe that our collection tube
technology can contribute to a higher level of sensitivity in
liquid biopsy testing."
"We are very pleased to highlight the robust real-world
performance of our Target Selector™ ctDNA assays for lung cancer,
as well as the utility of our CEE-Sure™ blood collection tubes
at this year's World Conference on Lung Cancer," said Biocept's
President and CEO Michael Nall. "We
believe that these results add to the body of evidence supporting
the clinical benefits of our proprietary molecular diagnostic
technologies and services, and further distinguish our novel
platform in the growing liquid biopsy segment."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including,
without limitation, statements as to the ability of our collection
tube technology to contribute to a higher level of sensitivity in
liquid biopsy testing, the clinical benefits of our
proprietary molecular diagnostic technologies and
services, our ability to improve the management, diagnosis and
treatment of cancer, and the ability of our tests to provide
clinically actionable information to oncologist and their
patients, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
Securities and Exchange Commission (SEC) filings. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/high-sensitivity-of-biocepts-target-selector-platform-using-cee-sure-blood-collection-tubes-to-be-featured-in-poster-presentation-at-the-2019-iaslc-world-conference-on-lung-cancer-300905630.html
SOURCE Biocept, Inc.